IL6 and breast cancer: It was revealed that T2DM individuals with CC genotype of IL-6 rs1800796 or GG genotype of HSPD1 rs2605039 were strongly associated with increased risk of breast cancer (OR (95%CI): 2.53 (1.45, 4.41) and OR (95%CI): 6.40 (2.29, 17.87), respectively) compared to non-T2DM individuals [48].